Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Evolution of frameworks for expediting access to new drugs in Japan

Abstract

Japanese clinical research and regulatory frameworks have evolved considerably in the past two decades to reduce the delay in the introduction of new drugs in Japan compared with other major markets. However, recently introduced changes related to access to unapproved drugs might have the opposite effect and might not benefit all patients.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Fujiwara, Y. & Kobayashi, K. Oncology drug clinical development and approval in Japan: the role of the pharmaceuticals and medical devices evaluation center (PMDEC). Crit. Rev. Oncol. Hematol. 42, 145–155 (2002).

    Article  Google Scholar 

  2. Kagayama, K. & Ono, S. Actual performance of Japanese clinical development and regulatory review (2000-2014). Research Paper Series No. 68 (November 2015), Office of Pharmaceutical Industry Research, The Japan Pharmaceutical Manufacturers Association (in Japanese) http://www.jpma.or.jp/opir/research/rs_068/article_068.html (2015)

  3. Fujiwara, Y., Yonemori, K., Shibata, T., Okita, N. & Ushirozawa, N. Japanese universal health care faces a crisis in cancer treatment. Lancet Oncol. 16, 251–252 (2015).

    Article  Google Scholar 

Download references

Acknowledgements

The author would like to thank B. A. Chabner, F. Pignatti, C. Matsuda and H. Ozaki for their valuable insights during the development of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasuhiro Fujiwara.

Ethics declarations

Competing interests

Y.F. has received a grant and a contract from the Ministry of Health, Labour and Welfare (MHLW), Japan, and a grant from the Japan Agency for Medical Research and Development between April 2013 and March 2016. He served on several committees or as a research program officer of the MHLW, Japan, the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the Japan Agency for Medical Research and Development. He has received lecture fees from AstraZeneca KK, Eisai Co. Ltd, Sanofi-Aventis KK, Daichi Sankyo Co. Ltd, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan KK, Yakult Honsha Co. Ltd and NEC corporation between April 2013 and March 2016. He has received research grants from Taiho Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, Takeda Bio Development Center Ltd, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan KK and Nippon Kayaku Co. Ltd between April 2013 and March 2016.

Supplementary information

Supplementary information S1 (figure)

Timeline of regulatory actions for expedited drug access in Japan, the European Union and the United States (PDF 136 kb)

Supplementary information S2 (table)

Recent regulatory systems for expedited drug access in Japan (PDF 117 kb)

Related links

Related links

FURTHER INFORMATION

Past decisions. Headquarters for Japanese Economic Recovery, Office of the Prime Minister

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fujiwara, Y. Evolution of frameworks for expediting access to new drugs in Japan. Nat Rev Drug Discov 15, 293–294 (2016). https://doi.org/10.1038/nrd.2016.68

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.68

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing